Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 3, 2005, Pages 336-343

  Wester, C William ^a,b   Kim, Soyeon ^a,c   Bussmann, Hermann ^a,b   Avalos, Ava ^a,b   Peter, Trevor F ^a,b   Gaolathe, Tendani ^d   Mujugira, Andrew ^d   Busang, Lesego ^a,e   Vanderwarker, Chris ^a,b   Cardiello, Peter ^a,b   Johnson, Onalethata ^a   Thior, Ibou ^a,b   Mazonde, Patson ^f   Moffat, Howard ^d   Essex, Max ^a,b   Marlink, Richard ^a,b  

^a BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^b Harvard AIDS Institute   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d PRINCESS MARINA HOSPITAL   (Botswana)

^e UNIVERSITY OF BOTSWANA   (Botswana)

^f Department of HIV AIDS Prevention and Care   (Botswana)

Author keywords

Africa; Antiretroviral treatment; Botswana; Highly active antiretroviral therapy; HIV AIDS; Public

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BOTSWANA; DRUG HYPERSENSITIVITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LIVER TOXICITY; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; BOTSWANA; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MANAGED CARE PROGRAMS; MEDICAL RECORDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PILOT PROJECTS; PROGRAM EVALUATION; PUBLIC SECTOR; TREATMENT OUTCOME;

EID: 27444443663     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000159668.80207.5b     Document Type: Article

References (44)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency infection. N Engl J Med. 1998;338:1933-1942.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients with human immunodeficiency infection. Lancet. 1998;352:1725-1730.
3. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
4. UNAIDS. Fact sheet. Access to HIV treatment and care, 2003. Available at: www.unaids.org.
5. The WHO and UNAIDS Global Initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005. WHO/UNAIDS Report: treating 3 million by 2005. Making it happen, the WHO strategy. 2003. Available at: http://www.unaids.org.
6. UNAIDS. Epidemic update AIDS, 2002. Available at: www.unaids.org.
7. Essex M, M'Boup S. Regional variations in the African epidemics. In: Essex M, M'Boup S, Kanki PJ, et al, eds. AIDS in Africa. 2nd ed. New York: Kluwer; 2002:631-640.
8. Novitsky VA, Montano MA, McLane MF, et al. Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana. J Virol. 1999;73:4427-4432.
9. Montano MA, Novitsky VA, Blackard JT, et al. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. J Virol. 1997;71:8657-8665.
10. Montano MA, Nixon CP, Ndung'u T, et al. Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. J Infect Dis. 2000;181:76-81.
11. Neilson JR, John GC, Carr JK, et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol. 1999;73:4393-4403.
12. Blackard JT, Renjifo B, Fawzi W, et al. HIV-1 LTR subtype and perinatal transmission. Virology. 2001;287:261-265.
13. Nellen JF, Wit FW, de Wolf F, et al. Virologie and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in The Netherlands. J Acquir Immune Defic Syndr. 2004;36:943-950.
14. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1 infected individuals to highly active antiretroviral therapy. AIDS. 2002;16:1139-1146.
15. Staehelin C, Rickenbach M, Low N, et al. Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS. 2003;17:2237-2244.
16. Morgan D, Mahe C, Mayanja B, et al. Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ. 2002;324:193-196.
17. del Amo J, Petruckevitch A, Phillips A, et al. Disease progression and survival in HIV-1 infected Africans in London. AIDS. 1998;12(10):1203-1209.
18. Gaston D, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS. 2003;17(Suppl 3):5-15.
19. Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS. 2003;17(Suppl 3):103-108.
20. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895.
21. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot anti-retroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34-40.
22. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-1370.
23. Djomand G, Roels T, Ellerbrok T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS. 2003;18(Suppl 3):5-15.
24. Landman R, Schiemann R, Thiam S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS. 2003;17:1017-1022.
25. Anabwani G, Jimbo W, eds. Botswana Guidelines on Antiretroviral Treatment. Gaborone: Botswana Ministry of Health; 2002.
26. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat. 1998;52:119-126.
27. Division of AIDS, NIAID. Division of AIDS Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; 1992.
28. Novitsky VA, Montano MA, McLane MF, et al. Molecular cloning and phylogenetic analysis of HIV-1 subtype C: a set of 23 full-length clones from Botswana. J Virol. 1999;73:4427-4432.
29. Ndung'u T, Renjifo B, Novitsky VA, et al. Molecular cloning and biological characterisation of full-length HIV-1C subtype C from Botswana. Virology. 2000;278:390-399.
30. Doualla-Bell F, Gaseitsiwe S, Ndung'u T, et al. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother. 2004;15:189-200.
31. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38:1159-1166.
32. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV infection. N Engl J Med. 2003;394:2304-2315.
33. Vinh-Kim N, Grennan T, Peschard K, et al. Antiretroviral use in Ouagadougou, Burkina Faso. AIDS. 2003;17(Suppl 3):109-111.
34. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 2003;341:1865-1873.
35. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients; the INCAS Trial. JAMA. 1998;279:930-937.
36. 3 at treatment initiation [poster presentation]. Presented at: XV International AIDS Conference; 2004; Bangkok.
37. Miller V, Phillips AN, Clotet B, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis. 2002;186:189-197.
38. Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS. 2004;18:2145-2151.
39. Ledru E, Sanou PT, Dembele M, et al. Prevention of wasting and opportunistic infections in HIV-infected patients in West Africa: a realistic and necessary strategy before antiretroviral treatment. Sante. 1999;9:293-300.
40. Lucas SB, DeCock KM, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. BMJ. 1994;308:1531-1533.
41. Freidl AC, Lederberger B, Flepp M, et al. Response to first protease-inhibitor-and efavirenz-containing antiretroviral combination therapy; the Swiss HIV Cohort Study. AIDS. 2001;15:1793-1800.
42. Wester CW, Bussmann H, Avalos A, et al. Establishment of a public adult antiretroviral treatment clinic in urban Botswana: lessons learned. J Clin Infect Dis. 2005;40(6).
43. Global HIV/AIDS Program of the World Bank. Provision of ARV therapy in resource limited settings: the challenges of drug resistance and adherence. June 17-18, 2003.
44. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report: accelerating action against AIDS in Africa, 2003. Available at: http://www.unaids.org.